Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

12

Other

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Dopamine transporter

12

Norepinephrine transporter

12

Synaptic vesicular amine transporter

12

catecholamine secretion

12

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

12

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1937

12

Unknown

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Attention deficit hyperactivity disorder

12

Moderate to severe binge eating disorder

12

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

12

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

12

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

New River Pharmaceuticals

12

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

14

All Match

Any Match

Exclude Selected

Exclude Selected

INN Stem

Chemical substance(-ine)

1

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

14

PUBCHEM

14

CAS

13

EPA CompTox

10

SMS_ID

8

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

NERVOUS SYSTEM

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

PSYCHOANALEPTICS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Centrally acting sympathomimetics

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

12

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 14 results

First page disabled
Previous page disabled
1
Next page
Next page

DEXTROAMPHETAMINE HYDROCHLORIDE

36013420H0

Export Data
Search for Structure

Status:

US Approved Rx (2023)

First marketed in 1937

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine transporter

Norepinephrine transporter

Synaptic vesicular amine transporter

catecholamine secretion

Conditions:

Attention deficit hyperactivity disorder

Attention deficit hyperactivity disorder

Moderate to severe binge eating disorder

Lisdexamfetamine (LDX) is a d-amphetamine (d-AMPH) pro-drug used to treat Attention Deficit and Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED). After oral administration, lisdexamfetamine dimesylate is rapidly absorbed from the gastroi...

ntestinal tract and converted to dextroamphetamine, which is responsible for the drug’s activity. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. Most common adverse reactions in children, adolescents and/or adults with ADHD were anorexia, anxiety, decreased appetite, decreased weight, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, and vomiting. Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents decrease amphetamine blood levels, while alkalinizing agents increase amphetamine blood levels. Needs to adjust Lisdexamfetamine dosage accordingly.

TMA-2

713Z3SL0TJ

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (RACEMIC)

LOMARDEXAMFETAMINE DIHYDROCHLORIDE

1N32846O21

Export Data
Search for Structure

Status:

US Approved Rx (2023)

First marketed in 1937

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine transporter

Norepinephrine transporter

Synaptic vesicular amine transporter

catecholamine secretion

Conditions:

Attention deficit hyperactivity disorder

Attention deficit hyperactivity disorder

Moderate to severe binge eating disorder

Lisdexamfetamine (LDX) is a d-amphetamine (d-AMPH) pro-drug used to treat Attention Deficit and Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED). After oral administration, lisdexamfetamine dimesylate is rapidly absorbed from the gastroi...

ntestinal tract and converted to dextroamphetamine, which is responsible for the drug’s activity. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. Most common adverse reactions in children, adolescents and/or adults with ADHD were anorexia, anxiety, decreased appetite, decreased weight, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, and vomiting. Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents decrease amphetamine blood levels, while alkalinizing agents increase amphetamine blood levels. Needs to adjust Lisdexamfetamine dosage accordingly.

DEXTROAMPHETAMINE

TZ47U051FI

Export Data
Search for Structure

Status:

US Approved Rx (2023)

First marketed in 1937

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine transporter

Norepinephrine transporter

Synaptic vesicular amine transporter

catecholamine secretion

Conditions:

Attention deficit hyperactivity disorder

Attention deficit hyperactivity disorder

Moderate to severe binge eating disorder

Lisdexamfetamine (LDX) is a d-amphetamine (d-AMPH) pro-drug used to treat Attention Deficit and Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED). After oral administration, lisdexamfetamine dimesylate is rapidly absorbed from the gastroi...

ntestinal tract and converted to dextroamphetamine, which is responsible for the drug’s activity. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. Most common adverse reactions in children, adolescents and/or adults with ADHD were anorexia, anxiety, decreased appetite, decreased weight, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, and vomiting. Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents decrease amphetamine blood levels, while alkalinizing agents increase amphetamine blood levels. Needs to adjust Lisdexamfetamine dosage accordingly.

LOMARDEXAMFETAMINE

Q5L4P8K8QZ

Export Data
Search for Structure

Status:

US Approved Rx (2023)

First marketed in 1937

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine transporter

Norepinephrine transporter

Synaptic vesicular amine transporter

catecholamine secretion

Conditions:

Attention deficit hyperactivity disorder

Attention deficit hyperactivity disorder

Moderate to severe binge eating disorder

Lisdexamfetamine (LDX) is a d-amphetamine (d-AMPH) pro-drug used to treat Attention Deficit and Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED). After oral administration, lisdexamfetamine dimesylate is rapidly absorbed from the gastroi...

ntestinal tract and converted to dextroamphetamine, which is responsible for the drug’s activity. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. Most common adverse reactions in children, adolescents and/or adults with ADHD were anorexia, anxiety, decreased appetite, decreased weight, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, and vomiting. Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents decrease amphetamine blood levels, while alkalinizing agents increase amphetamine blood levels. Needs to adjust Lisdexamfetamine dosage accordingly.

DEXTROAMPHETAMINE TARTRATE

3913Q2TAOZ

Export Data
Search for Structure

Status:

US Approved Rx (2023)

First marketed in 1937

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine transporter

Norepinephrine transporter

Synaptic vesicular amine transporter

catecholamine secretion

Conditions:

Attention deficit hyperactivity disorder

Attention deficit hyperactivity disorder

Moderate to severe binge eating disorder

Lisdexamfetamine (LDX) is a d-amphetamine (d-AMPH) pro-drug used to treat Attention Deficit and Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED). After oral administration, lisdexamfetamine dimesylate is rapidly absorbed from the gastroi...

ntestinal tract and converted to dextroamphetamine, which is responsible for the drug’s activity. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. Most common adverse reactions in children, adolescents and/or adults with ADHD were anorexia, anxiety, decreased appetite, decreased weight, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, and vomiting. Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents decrease amphetamine blood levels, while alkalinizing agents increase amphetamine blood levels. Needs to adjust Lisdexamfetamine dosage accordingly.

DEXTROAMPHETAMINE MONOSACCHARATE

283TUU52FG

Export Data
Search for Structure

Status:

US Approved Rx (2023)

First marketed in 1937

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine transporter

Norepinephrine transporter

Synaptic vesicular amine transporter

catecholamine secretion

Conditions:

Attention deficit hyperactivity disorder

Attention deficit hyperactivity disorder

Moderate to severe binge eating disorder

Lisdexamfetamine (LDX) is a d-amphetamine (d-AMPH) pro-drug used to treat Attention Deficit and Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED). After oral administration, lisdexamfetamine dimesylate is rapidly absorbed from the gastroi...

ntestinal tract and converted to dextroamphetamine, which is responsible for the drug’s activity. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. Most common adverse reactions in children, adolescents and/or adults with ADHD were anorexia, anxiety, decreased appetite, decreased weight, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, and vomiting. Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents decrease amphetamine blood levels, while alkalinizing agents increase amphetamine blood levels. Needs to adjust Lisdexamfetamine dosage accordingly.

DEXTROAMPHETAMINE ADIPATE

YYI1A8W4TQ

Export Data
Search for Structure

Status:

US Approved Rx (2023)

First marketed in 1937

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine transporter

Norepinephrine transporter

Synaptic vesicular amine transporter

catecholamine secretion

Conditions:

Attention deficit hyperactivity disorder

Attention deficit hyperactivity disorder

Moderate to severe binge eating disorder

Lisdexamfetamine (LDX) is a d-amphetamine (d-AMPH) pro-drug used to treat Attention Deficit and Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED). After oral administration, lisdexamfetamine dimesylate is rapidly absorbed from the gastroi...

ntestinal tract and converted to dextroamphetamine, which is responsible for the drug’s activity. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. Most common adverse reactions in children, adolescents and/or adults with ADHD were anorexia, anxiety, decreased appetite, decreased weight, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, and vomiting. Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents decrease amphetamine blood levels, while alkalinizing agents increase amphetamine blood levels. Needs to adjust Lisdexamfetamine dosage accordingly.

LISDEXAMFETAMINE SULFATE

49I8A1C26Y

Export Data
Search for Structure

Status:

US Approved Rx (2023)

First marketed in 1937

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine transporter

Norepinephrine transporter

Synaptic vesicular amine transporter

catecholamine secretion

Conditions:

Attention deficit hyperactivity disorder

Attention deficit hyperactivity disorder

Moderate to severe binge eating disorder

Lisdexamfetamine (LDX) is a d-amphetamine (d-AMPH) pro-drug used to treat Attention Deficit and Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED). After oral administration, lisdexamfetamine dimesylate is rapidly absorbed from the gastroi...

ntestinal tract and converted to dextroamphetamine, which is responsible for the drug’s activity. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. Most common adverse reactions in children, adolescents and/or adults with ADHD were anorexia, anxiety, decreased appetite, decreased weight, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, and vomiting. Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents decrease amphetamine blood levels, while alkalinizing agents increase amphetamine blood levels. Needs to adjust Lisdexamfetamine dosage accordingly.

LISDEXAMFETAMINE

H645GUL8KJ

Export Data
Search for Structure

Status:

US Approved Rx (2023)

First marketed in 1937

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine transporter

Norepinephrine transporter

Synaptic vesicular amine transporter

catecholamine secretion

Conditions:

Attention deficit hyperactivity disorder

Attention deficit hyperactivity disorder

Moderate to severe binge eating disorder

Lisdexamfetamine (LDX) is a d-amphetamine (d-AMPH) pro-drug used to treat Attention Deficit and Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED). After oral administration, lisdexamfetamine dimesylate is rapidly absorbed from the gastroi...

ntestinal tract and converted to dextroamphetamine, which is responsible for the drug’s activity. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. Most common adverse reactions in children, adolescents and/or adults with ADHD were anorexia, anxiety, decreased appetite, decreased weight, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, and vomiting. Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents decrease amphetamine blood levels, while alkalinizing agents increase amphetamine blood levels. Needs to adjust Lisdexamfetamine dosage accordingly.

Showing 1 - 10 of 14 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1